Genprex, Inc. Logo

Genprex, Inc.

GNPX

(1.0)
Stock Price

0,91 USD

-395.81% ROA

-409.49% ROE

-0.03x PER

Market Cap.

905.475,00 USD

0% DER

0% Yield

-98082.2% NPM

Genprex, Inc. Stock Analysis

Genprex, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Genprex, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (1.07x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

4 ROE

Negative ROE (-147.33%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-194.97%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Genprex, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Genprex, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Genprex, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Genprex, Inc. Revenue
Year Revenue Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Genprex, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2015 201.962
2016 354.883 43.09%
2017 289.934 -22.4%
2018 971.427 70.15%
2019 1.967.007 50.61%
2020 7.302.923 73.07%
2021 8.607.751 15.16%
2022 11.510.074 25.22%
2023 18.466.184 37.67%
2023 17.616.605 -4.82%
2024 6.666.088 -164.27%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Genprex, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 865.696
2016 3.776.414 77.08%
2017 3.019.171 -25.08%
2018 11.386.229 73.48%
2019 8.702.596 -30.84%
2020 10.635.881 18.18%
2021 10.970.472 3.05%
2022 12.295.070 10.77%
2023 12.664.228 2.91%
2023 13.443.961 5.8%
2024 19.397.888 30.69%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Genprex, Inc. EBITDA
Year EBITDA Growth
2015 -1.067.658
2016 -4.131.297 74.16%
2017 -3.309.025 -24.85%
2018 -12.328.472 73.16%
2019 -10.641.698 -15.85%
2020 -17.938.804 40.68%
2021 -19.578.223 8.37%
2022 -23.805.144 17.76%
2023 -31.077.180 23.4%
2023 -31.060.570 -0.05%
2024 -26.063.960 -19.17%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Genprex, Inc. Gross Profit
Year Gross Profit Growth
2015 0
2016 0 0%
2017 0 0%
2018 -5.885 100%
2019 -13.070 54.97%
2020 -22.777 42.62%
2021 -22.534 -1.08%
2022 -23.830.719 99.91%
2023 0 0%
2023 -15.004 100%
2024 -9.152 -63.94%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Genprex, Inc. Net Profit
Year Net Profit Growth
2015 -1.069.722
2016 -4.132.159 74.11%
2017 -3.314.157 -24.68%
2018 -12.372.339 73.21%
2019 -10.654.768 -16.12%
2020 -17.923.959 40.56%
2021 -19.590.491 8.51%
2022 -29.463.105 33.51%
2023 -30.992.972 4.94%
2023 -30.860.461 -0.43%
2024 -25.983.380 -18.77%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Genprex, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 -23
2016 -15 -46.67%
2017 -12 -36.36%
2018 -36 68.57%
2019 -27 -34.62%
2020 -20 -30%
2021 -18 -17.65%
2022 -20 10.53%
2023 -1 0%
2023 -23 100%
2024 -12 -83.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Genprex, Inc. Free Cashflow
Year Free Cashflow Growth
2015 -709.545
2016 -1.337.797 46.96%
2017 -2.235.015 40.14%
2018 -6.949.851 67.84%
2019 -7.865.620 11.64%
2020 -16.272.336 51.66%
2021 -14.368.720 -13.25%
2022 -17.838.699 19.45%
2023 -24.809.986 28.1%
2023 -4.756.952 -421.55%
2024 -5.778.854 17.68%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Genprex, Inc. Operating Cashflow
Year Operating Cashflow Growth
2015 -688.261
2016 -1.248.263 44.86%
2017 -2.171.594 42.52%
2018 -6.846.534 68.28%
2019 -6.918.721 1.04%
2020 -13.935.086 50.35%
2021 -14.284.924 2.45%
2022 -17.778.964 19.65%
2023 -24.738.603 28.13%
2023 -4.735.196 -422.44%
2024 -5.795.842 18.3%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Genprex, Inc. Capital Expenditure
Year Capital Expenditure Growth
2015 21.284
2016 89.534 76.23%
2017 63.421 -41.17%
2018 103.317 38.62%
2019 946.899 89.09%
2020 2.337.250 59.49%
2021 83.796 -2689.21%
2022 59.735 -40.28%
2023 71.383 16.32%
2023 21.756 -228.11%
2024 -16.988 228.07%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Genprex, Inc. Equity
Year Equity Growth
2015 393.737
2016 1.624.868 75.77%
2017 428.574 -279.13%
2018 8.881.135 95.17%
2019 3.023.545 -193.73%
2020 30.916.490 90.22%
2021 41.276.991 25.1%
2022 22.274.740 -85.31%
2023 7.416.384 -200.35%
2023 12.305.492 39.73%
2024 4.345.550 -183.17%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Genprex, Inc. Assets
Year Assets Growth
2015 410.091
2016 1.910.529 78.54%
2017 1.259.538 -51.68%
2018 9.268.956 86.41%
2019 3.534.229 -162.26%
2020 31.367.214 88.73%
2021 42.862.286 26.82%
2022 25.085.027 -70.87%
2023 10.670.592 -135.09%
2023 16.643.625 35.89%
2024 6.604.810 -151.99%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Genprex, Inc. Liabilities
Year Liabilities Growth
2015 16.354
2016 285.661 94.28%
2017 830.964 65.62%
2018 387.821 -114.26%
2019 510.684 24.06%
2020 450.724 -13.3%
2021 1.585.295 71.57%
2022 2.810.287 43.59%
2023 3.254.208 13.64%
2023 4.338.133 24.99%
2024 2.259.260 -92.02%

Genprex, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-12.09
Price to Earning Ratio
-0.03x
Price To Sales Ratio
39.11x
POCF Ratio
-0.04
PFCF Ratio
-0.04
Price to Book Ratio
0.17
EV to Sales
-67.1
EV Over EBITDA
0.06
EV to Operating CashFlow
0.07
EV to FreeCashFlow
0.07
Earnings Yield
-34.57
FreeCashFlow Yield
-23
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
23.38
Graham NetNet
0.09

Income Statement Metrics

Net Income per Share
-12.09
Income Quality
0.8
ROE
-3.19
Return On Assets
-5.81
Return On Capital Employed
-13.71
Net Income per EBT
1
EBT Per Ebit
0.99
Ebit per Revenue
-985.8
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
561.7
Research & Developement to Revenue
573.14
Stock Based Compensation to Revenue
220.71
Gross Profit Margin
0.64
Operating Profit Margin
-985.8
Pretax Profit Margin
-980.82
Net Profit Margin
-980.82

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-9.62
Free CashFlow per Share
-9.63
Capex to Operating CashFlow
-0
Capex to Revenue
1.37
Capex to Depreciation
2.62
Return on Invested Capital
-6.03
Return on Tangible Assets
-3.96
Days Sales Outstanding
0
Days Payables Outstanding
35414.77
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.01
Inventory Turnover
0
Capex per Share
0.01

Balance Sheet

Cash per Share
1,14
Book Value per Share
2,01
Tangible Book Value per Share
2.01
Shareholders Equity per Share
2.01
Interest Debt per Share
0.03
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.09
Current Ratio
1.95
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
2137286
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Genprex, Inc. Dividends
Year Dividends Growth

Genprex, Inc. Profile

About Genprex, Inc.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

CEO
Mr. Ryan M. Confer M.S.
Employee
21
Address
3300 Bee Cave Road
Austin, 78746

Genprex, Inc. Executives & BODs

Genprex, Inc. Executives & BODs
# Name Age
1 Mr. Ryan M. Confer M.S.
President, Chief Executive Officer, Chief Financial Officer & Director
70
2 Dr. Jack A. Roth F.A.C.S., M.D.
Chairman of Scientific & Medical Advisory Board
70
3 Dr. Suzanne Thornton-Jones Ph.D.
Senior Vice President of Regulatory Affairs & Quality
70
4 Mr. David M. Schloss
Senior Vice President of Human Resources
70
5 Dr. Mark S. Berger M.D.
Chief Medical Officer
70
6 Mr. Thomas C. Gallagher Esq.
Senior Vice President of Intellectual Property & Licensing
70

Genprex, Inc. Competitors